HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bocchi's Sanitation Flies In Face Of Regs, FDA Finds Following Medline Recall

Executive Summary

Warning letter to Bocchi Laboratories details violations of FDA regulations agency inspectors found in an inspection of firm's facility from late March through early June 2018 "in response to an outbreak of Burkholderia cepacia associated with" a cleanser it manufactures. In addition to product adulteration due to microbial contamination, FDA found Bocchi in violation of drug GMPs because products were labeled with indications rendering them drugs under FDA regulations.

You may also be interested in...



Store Brand Cough/Cold OTCs, Alterna Conditioners Among Recent Recalls

Sun Pharmaceutical, P&L Developments and Preferred Pharmaceutical made OTCs for customers including CVS, Target and Walgreens. Latest updates to FDA recalls database also includes polypeptide- and colostrum-containing immunity support supplements made by APS BioGroup and Alterna anti-aging, moisture-replenishing conditioning milk and cream marketed by Henkel Corp.

'Blood Disorders' Supplement, More Bocchi Labs Hair Care Products Recalled

McDaniel Life-Line recalls its Indian Herb supplement after FDA determined it was marketed without an NDA for claims including "blood disorders." For third time in less than a year, John Paul Mitchell Systems brand and other shampoos recalled by manufacturer Bocchi Labs due to potential contamination; other health, beauty and wellness product recalls.

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

Topics

UsernamePublicRestriction

Register

RS148574

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel